Early heart risk monitoring for breast cancer chemo
Part of Cancer, Heart & circulation, Injuries & trauma, Skin clinical trials.
This study tests a method to predict and warn about heart damage from a common type of breast cancer chemotherapy. If you have HER2-positive breast cancer and will receive anthracycline drugs, this trial may help monitor your heart health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have HER2-positive breast cancer at stage I, II, or III.
- You will receive chemotherapy with drugs called anthracyclines, followed by trastuzumab (Herceptin) therapy.
- Your heart's pumping strength (LVEF) is at least 53% before treatment starts.
- You have not had prior treatment with anthracyclines or radiation to the chest.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks how well the heart handles HER2-targeted therapy (like Herceptin) during the first year of treatment for early-stage breast cancer. It helps keep you safe by checking heart function closely.
This study looks at how breast cancer medicines affect the heart. It may help doctors better prevent, spot early, and manage heart side effects from trastuzumab and/or anthracycline chemotherapy.
This study grows heart muscle cells from your blood or skin to better understand why some people develop heart problems from HER2 cancer treatments. You may be helping researchers learn how to predict and prevent treatment-related heart damage.
This study tests a supervised exercise program for people with breast cancer who are about to start or are already in chemotherapy. The goal is to see if this type of rehabilitation helps keep your heart strong and improves your overall well-being during treatment.
This study helps doctors find the best way to monitor heart health in women with HER2-positive breast cancer who are receiving a type of targeted chemotherapy. The goal is to catch any heart problems early and keep you safe during treatment.
This study watches how chemotherapy and HER2-targeted drugs affect your heart during early-stage breast cancer treatment. Researchers use heart scans to catch any changes early and understand how to protect heart health.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.